These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 22363732

  • 1. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A, Pilz G, Einhaeupl M, Oppermann K, Hitzl W, Wipfler P, Sellner J, Golaszewski S, Afazel S, Haschke-Becher E, Trinka E, Kraus J.
    PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
    [Abstract] [Full Text] [Related]

  • 2. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
    Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D'Agosto G, Cordiali-Fei P.
    Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
    McCormack PL.
    Drugs; 2013 Sep; 73(13):1463-81. PubMed ID: 23912625
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B.
    J Neurol Sci; 2012 Mar 15; 314(1-2):138-42. PubMed ID: 22050952
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007621. PubMed ID: 21975773
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.
    Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E.
    J Clin Immunol; 2011 Aug 05; 31(4):623-31. PubMed ID: 21491095
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab effects on immune cell responses in multiple sclerosis.
    Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guérette C, Antel JP, Fournier A, Grand'Maison F, Bar-Or A.
    Ann Neurol; 2006 May 05; 59(5):748-54. PubMed ID: 16634035
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
    Jilek S, Mathias A, Canales M, Lysandropoulos A, Pantaleo G, Schluep M, Du Pasquier RA.
    Mult Scler; 2014 Jun 05; 20(7):837-42. PubMed ID: 24258149
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M, Zingaropoli MA, Bellizzi A, Morreale M, Pontecorvo S, D'Abramo A, Oliva A, Anzivino E, Lo Menzo S, D'Agostino C, Mastroianni CM, Millefiorini E, Pietropaolo V, Francia A, Vullo V, Ciardi MR.
    PLoS One; 2016 Jun 05; 11(8):e0160277. PubMed ID: 27486658
    [Abstract] [Full Text] [Related]

  • 18. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
    Boziki MK, Karapanayotides T, Papadopoulos G, Lagoudaki R, Melo P, Bakirtzis C, Nikolaidis I, Gounari E, Tsavdaridou V, Skoura L, Afrantou T, Tatsi T, Grigoriadou E, Polyzoidou E, Mandoras N, Giantzi V, Kalogera-Fountzila A, Ioannidis P, Parissis D, Pelidou SH, Zoidou S, Grigoriadis N.
    Neurol Res; 2020 Mar 05; 42(3):209-221. PubMed ID: 32048570
    [Abstract] [Full Text] [Related]

  • 19. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.
    de Andrés C, Teijeiro R, Alonso B, Sánchez-Madrid F, Martínez ML, Guzmán de Villoria J, Fernández-Cruz E, Sánchez-Ramón S.
    PLoS One; 2012 Mar 05; 7(4):e34103. PubMed ID: 22496780
    [Abstract] [Full Text] [Related]

  • 20. alpha4-Integrin antagonism with natalizumab: effects and adverse effects.
    Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC.
    J Neurol; 2008 Dec 05; 255 Suppl 6():58-65. PubMed ID: 19300961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.